Affiliation:
1. Korea University Ansan Hospital
2. Konkuk University School of Medicine
3. Ewha Womans University Seoul Hospital
4. Yonsei University College of Medicine
5. Soonchunhyang University Cheonan Hospital
6. NTL Medical Institute
7. Gachon University College of Medicine, Gil Medical Center
8. Korea University Guro Hospital
Abstract
Abstract
Cervical cancer, the fourth most common cancer among women worldwide, often proves fatal and stems from precursor lesions caused by high-risk human papillomavirus (HR-HPV) infection. Accurate and early diagnosis is crucial for effective treatment. Current screening methods, such as the Pap test, liquid-based cytology (LBC), visual inspection with acetic acid (VIA), and HPV DNA testing, have limitations, requiring confirmation through colposcopy. This study introduces CerviCARE® AI, an artificial intelligence (AI) analysis software, to address colposcopy challenges. It automatically analyzes Tele-cervicography images, distinguishing between low-grade and high-grade lesions. In a multicenter retrospective study, CerviCARE® AI achieved a remarkable sensitivity of 98% for high-risk groups (P2, P3, HSIL or higher, CIN2 or higher) and a specificity of 95.5%. These findings underscore CerviCARE® AI's potential as a valuable diagnostic tool for highly accurate identification of cervical precancerous lesions. Its integration into clinical practice could enhance early detection and reduce screening disparities, especially in regions with limited access to skilled colposcopists. While further prospective research is needed to validate its clinical utility, this AI system holds promise for improving cervical cancer screening and lessening the burden of this deadly disease.
Publisher
Research Square Platform LLC